Clinical Trials Logo

Clinical Trial Summary

Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and transcriptional regulation that is always "turned on" despite the absence of estrogen. Patients with ESR1 mutations are expected to have decreased binding affinity for tamoxifen and thus may be underdosed on standard therapy. [18F]-fluoroestradiol Positron Emission Tomography/Computed tomography (FES-PET/CT) imaging is a novel functional imaging technique that can non-invasively measure ERα expression and inhibition in metastatic ERα+ breast cancer. The proposed a pilot study uses FES-PET/CT imaging to measure ERα blockade to determine the optimal dose of tamoxifen in patients with ESR1 mutations.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04174352
Study type Interventional
Source University of Wisconsin, Madison
Contact cancer connect
Phone 800-622-8922
Email clinicaltrials@cancer.wisc.edu
Status Recruiting
Phase Early Phase 1
Start date October 20, 2020
Completion date December 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05814224 - Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA N/A
Not yet recruiting NCT06382948 - Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Phase 3